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Abstract
Background:  Pompe disease (PD) is a metabolic myopathy caused by α-glucosidase (GAA)
deficiency and characterized by generalized glycogen storage. Heterogeneous GAA gene mutations
result in wide phenotypic variability, ranging from the severe classic infantile presentation to the
milder intermediate and late-onset forms. Enzyme replacement therapy (ERT) with recombinant
human GAA (rhGAA), the only treatment available for PD, intriguingly shows variable efficacy in
different PD patients. To investigate the mechanisms underlying the variable response to ERT, we
studied cell morphology of PD fibroblasts, the distribution and trafficking of the cation-independent
mannose-6-phosphate receptor (CI-MPR) that mediates rhGAA uptake, and rhGAA uptake itself.
Results: We observed abnormalities of cell morphology in PD cells. Electron microscopy analysis
showed accumulation of multivesicular bodies and expansion of the Golgi apparatus, and
immunolocalization and western blot analysis of LC3 showed activation of autophagy.
Immunofluorescence analysis showed abnormal intracellular distribution of CI-MPR in PD
fibroblasts, increased co-localization with LC3 and reduced availability of the receptor at the plasma
membrane. The recycling of CI-MPR from the plasma membrane to the trans-Golgi network was
also impaired. All these abnormalities were more prominent in severe and intermediate PD
fibroblasts, correlating with disease severity. In severe and intermediate PD cells rhGAA uptake
and processing were less efficient and correction of GAA activity was reduced.
Conclusion: These results indicate a role for disrupted CI-MPR trafficking in the variable response
to ERT in PD and have implications for ERT efficacy and optimization of treatment protocols.
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Background
Pompe disease (PD, glycogenosis type II) is a metabolic
myopathy, with an estimated incidence of 1:40,000, char-
acterized by intra-lysosomal glycogen storage [1]. PD is
caused by mutations in the acid α-glucosidase (GAA)
gene, encoding the lysosomal hydrolase α-glucosidase
(acid maltase, GAA, E.C.3.2.1.20). GAA is synthesized in
the endoplasmic reticulum as a 110 kDa precursor, which
undergoes N-glycan processing in the Golgi apparatus,
and is proteolytically processed in the lysosomes into
active polypeptides of 76 and 70 kDa, through an inter-
mediate molecular form of 95 kDa [2,3]. In PD, glycogen
accumulation occurs in almost every organ and system,
but is particularly evident in skeletal muscle and heart, the
sites of the most debilitating clinical manifestations [1].
Different mutations of the GAA gene result in a wide phe-
notypic spectrum, with respect to age of onset of manifes-
tations, rate of disease progression and variable
association of symptoms. The different clinical forms of
PD range from a devastating classic infantile phenotype,
characterized by early onset, severe cardiomyopathy and
early lethality, to intermediate phenotypes and late onset
(childhood, juvenile or adult) forms in which cardiac
involvement is absent or mild [1,4,5].
The past two decades have been characterized by impres-
sive progress in the treatment of lysosomal storage dis-
eases (LSDs), with the development of innovative
therapies, including haematopoietic stem cell transplanta-
tion (HSCT) [6], enzyme replacement therapy (ERT) [7],
substrate reduction therapy (SRT) [8] and enzyme
enhancement therapy (EET) by pharmacological chaper-
ons [9,10]. Among these approaches, ERT represented a
major breakthrough in the treatment of LSDs, initially
used for the treatment of Gaucher disease and now avail-
able for several other LSDs.
ERT with recombinant human GAA (rhGAA) is presently
the only approach for the treatment of PD patients. The
first clinical trials, based on the use of an enzyme derived
from transgenic rabbits, demonstrated that ERT was effec-
tive in improving cardiomyopathy, survival, growth and
motor function in classic infantile PD patients [11]. ERT
has been subsequently extended to PD patients with other
phenotypes. The results of the published studies showed
dramatic improvements of cardiac, respiratory and motor
function in some patients, whereas in others ERT failed to
cause significant clinical improvement [12,13]. This sug-
gests that the clinical outcome in response to ERT may be
variable, correlating with histological evidence of poor
glycogen clearance [14], and that correction of glycogen
storage in skeletal muscle is particularly challenging. Fac-
tors such as age at the start of treatment, stage of skeletal
muscle damage, antibody responses [15], insufficient tar-
geting of rhGAA to skeletal muscle and high clearance of
the enzyme by the liver [16] play a role in ERT efficacy,
although the reasons for the variable responses of differ-
ent PD patients are not completely clear and other factors,
such as patients' genotype and abnormalities of cell func-
tions, may also be implicated.
We postulated that an impairment of house-keeping cel-
lular functions and membrane trafficking resulting from
abnormal substrate storage is an additional and impor-
tant factor influencing the efficacy of ERT in PD, and pos-
sibly in other LSDs.
To date, several studies have pointed to the role of a vari-
ety of structural and biochemical responses triggered by
intracellular storage, which are considered to be responsi-
ble for the pathogenetic manifestation of LSDs. These
abnormalities include activation of inflammation by
cytokines, impairment of the autophagic pathway, altera-
tions of signal transduction pathways, altered calcium
homeostasis and apoptosis and abnormalities of intracel-
lular trafficking [17,18].
Abnormal intracellular trafficking of lipids and proteins
may affect the function of membrane-bound proteins,
such as receptors, and ligands. The cation-independent
300 kDa mannose-6-phosphate receptor (CI-MPR) is of
particular interest as it is a key player in the internalization
of exogenous enzymes, and for the possible consequences
of deranged CI-MPR function on ERT efficacy. CI-MPR is
an integral membrane glycoprotein that follows a com-
plex and finely regulated itinerary from the trans-Golgi
network (TGN), where it binds newly synthesized lyso-
somal hydrolases, travels through the early endosomes
towards the late endosomal compartments, and recycles
back to the TGN. At the steady state, a fraction (approxi-
mately 10%) of CI-MPR is located on cell surface, where it
mediates the uptake of lysosomal enzymes, is internalized
in the early endocytic compartment and then recycled
again to the plasma membrane through the endocytic
recycling compartment (ERC) [19].
To address the consequences of abnormalities of cellular
morphology and function on CI-MPR subcellular locali-
zation, we studied fibroblasts from PD patients with dif-
ferent genotypes and phenotypes. We demonstrated that
in these cells, which showed abnormalities of cellular
morphology, CI-MPR is mislocalized and its availability
at the plasma membrane is reduced. These abnormalities
in CI-MPR distribution result in a less efficient uptake of
rhGAA by PD fibroblasts.
Results
PD fibroblasts show abnormalities of cell morphology
In order to determine whether PD fibroblasts display
abnormalities of cell morphology and trafficking we tookPathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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advantage of five fibroblast cell lines from PD patients
with different genotypes and associated phenotypes
(Table 1). All cell lines studied had nearly absent or
reduced GAA activity due to mutations in the GAA gene,
compared with age-matched control fibroblasts.
Electron microscopy (EM) analysis of PD cells showed
intralysosomal storage of glycogen, a typical hallmark of
the disease [1,14,20], and an increased number of large
membrane-bound structures containing intralumenal
stacked, reticulated or whorled osmiophilic membranes
known as 'myelin figures'. Some of these structures had
features typical of endosomal multivesicular bodies
(MVBs) (Figure 1a, black asterisks), while others exhibited
features typical of autophagosomes (white asterisks), with
double membranes (black arrows) and cytoplasmic-like
content. In intermediate and severe PD fibroblasts, glyco-
gen storage (white arrows) was evident as electron-dense
spots either within endolysosomes and autophagosomes
or dispersed in the cytoplasm. The percentage of endolys-
osome volume occupied by glycogen ranged from 14% in
juvenile PD fibroblasts, to 43% in intermediate PD
fibroblasts to 65% in severe PD fibroblasts. On average,
MVBs and autophagosomes appeared to be more promi-
nent in cells from severely affected patient as compared
with control cells and with cells from patients with milder
phenotypes, suggesting an expansion of the autophagic
compartment in severe PD fibroblasts.
This finding was also confirmed by immunofluorescence
and western blot analysis of the microtubule-associated
protein 1 light chain 3 (LC3). LC3, encoded by the mam-
malian homolog of the yeast atg8 gene, and its processed
phospholipid-conjugated LC3-II molecular form, local-
ized in the autophagosomes, are known markers of
autophagy [21-23]. Fibroblasts were studied both under
standard culture conditions in DMEM medium and after
starvation (amino acid deprivation for 2 hours), a stimu-
lus for autophagy [22,23].
Immunofluorescence microscopy (Figure 1b) showed
punctated LC3 signal in patients' cells either under basal
conditions or after starvation. The LC3 signal was local-
ized peripherally in multiple vesicles or cup-shaped struc-
tures, with a pattern compatible with a membrane-
anchored protein localized in the autophagosomal com-
partment. This pattern was most prominent in PD fibrob-
lasts from patients with the severe and intermediate
forms. Starvation of cells in amino acid-deprived EBSS
medium resulted in increased LC3 signal in controls and
in juvenile PD fibroblasts, whereas no substantial change
in LC3 staining was appreciable in severe and intermedi-
ate PD cells. To perform a quantitative analysis of LC3-
positive spots at steady state and under basal culturing
conditions, confocal images from control and PD fibrob-
lasts stained with anti-LC3 antibody were processed by
ImageJ (using the analysing particles module and consid-
ering as minimum size four pixels). The cells from con-
trols and severe PD were classified into three groups based
on the number of LC3-positive spots (1 to 10 spots, 11 to
40 spots and 41 to 200 spots). The analysis showed that
the population of cells containing increased number of
LC3-positive spots was more represented in severe PD
fibroblasts (Table 2).
Western blot analysis (Figure 1c) of LC3 showed results
consistent with those of immunofluorescence analysis in
cells cultured under basal conditions, with an increased
amount of LC3-II in cells from intermediate and severe
PD patients compared with controls. After starvation all
cells showed increased LC3-II expression. The ratio
between LC3-II and LC3-I was increased in severe and
intermediate PD fibroblasts under basal conditions, com-
pared with controls and juvenile PD cells.
EM analysis showed that the overall organization of the
Golgi stacks and the number of cisternae per stack (four
cisternae/stack) were preserved in PD fibroblasts com-
pared with control cells; however, the average length of
Golgi cisternae, ranging from 600 nm to 1 μm in control
fibroblasts, reached 2 μm in fibroblasts from patients with
severe and intermediate PD (Figure 2b).
We also studied the distribution of several Golgi markers
at immunofluorescence level, including that of GM130
and mannosidase II, markers of the cis and medial Golgi
Table 1: Pompe disease fibroblast cell lines, phenotype, genotype and residual GAA activity
Cell line Phenotype Genotype GAA relative activity
DNA mutation Protein mutation
1 severe c.1101G>A/c.1927G>A p.W367X/p.G643R 0.3%
2 intermediate c.1655T>C/c.1655T>C p.L552P/p.L552P 1.2%
3 intermediate c.1655T>C/c.-35C>A p.L552P/abn. splicing 1.6%
4 juvenile c.1645G>C/c.692+1G>C p.G549R/abn. splicing 3.2%
5 juvenile c.-45T>G/unknown abn. splicing/unknown 5.2%
GAA relative activity is expressed as percentage of normal (100%). Normal range of GAA activity in fibroblasts 58.5 +/- 28.1PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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Figure 1 (see legend on next page)PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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apparatus (Figure 3a), of golgin-97 (Figure 3b), γ-adaptin
and TGN46 (not shown), which are localized in the TGN.
The staining pattern of these Golgi markers consisted of a
compact perinuclear structure in control cells and of a
more reticular distended structure in PD fibroblasts (con-
sistent with the increased cisternae length observed at
EM). The 'distension' of the Golgi staining pattern was
more prominent in severe and intermediate PD fibrob-
lasts, thus apparently correlating with disease severity.
CI-MPR is mislocalized and its availability at the plasma 
membrane is reduced in PD fibroblasts
The uptake of exogenous lysosomal enzymes at the
plasma membrane and their delivery to lysosomes is per-
formed by the CI-MPR [19]. Thus a correct CI-MPR local-
ization and function is relevant for the efficacy of ERT.
We studied CI-MPR distribution by confocal analysis of
PD fibroblasts, and compared the results with those
obtained from age-matched control fibroblasts. Scoring of
CI-MPR distribution showed a high rate of cells with
reduced or dispersed signal in severe PD (75% of the cells)
and intermediate (55%) PD fibroblasts as compared with
the compact juxtanuclear pattern observed in control cells
(Figure 4a). Also the co-localization with the TGN marker
TGN46 was poorer in intermediate and severe PD fibrob-
lasts as compared with control cells (Figure 4b). Fibrob-
lasts from patients with juvenile PD did not show
substantial abnormalities of the distribution of CI-MPR or
of TGN46.
We evaluated the amount of CI-MPR at the plasma mem-
brane in PD and control fibroblasts as the availability of
CI-MPR at the plasma membrane is of particular interest
for its involvement in the uptake of exogenous enzymes
and in the efficacy of ERT. To this end, cells were incu-
bated with an anti-CI-MPR antibody in ice-cold medium
and then analyzed on a fluorescence-activated cell sorter
(FACS). Under these conditions, internalization of the CI-
MPR-antibody complexes located on plasma membrane
is prevented, and the anti-MPR antibody labels only the
CI-MPR exposed at the plasma membrane. The percentage
of CI-MPR positive cells was normalized, taking that
observed in control fibroblasts as 100%. The number of
CI-MPR-positive cells was significantly reduced in two
(severe and intermediate) PD fibroblast cell lines (Figure
4c), with average values of 45 and 65%, respectively. In a
juvenile PD cell line the percentage of positive cells was
also reduced, albeit to a lesser extent (75%).
The recycling of CI-MPR from the plasma membrane is 
reduced in PD fibroblasts
To investigate the trafficking of CI-MPR through the endo-
cytic pathway, an essential route for the internalization of
exogenous lysosomal enzymes, we applied a synchroniza-
tion protocol including a pulse at 18°C with anti-CI-MPR
antibody and then a chase at 37°C, in order to follow how
much of the pool of plasma membrane receptor is able to
reach early and late endosomes. Low temperature is per-
missive for transport from the plasma membrane to early
endosomal compartment but delays the recycling path-
way and the kinetics of endosome acidification [24].
Pompe disease fibroblasts show expansion of the autophagic compartment Figure 1 (see previous page)
Pompe disease fibroblasts show expansion of the autophagic compartment. A) Electron microscopy of control and 
juvenile human fibroblasts (left panel) and intermediate and severe human fibroblasts (right panel). The latter two cell lines 
show increased number of multivesicular bodies (black asterisks) and of autophagosomes or autolysosomes (white asterisks) 
characterized by double membranes (black arrows) and cytoplasmic content. Also evident is the glycogen accumulation in 
Pompe disease (PD) cells (white arrows). Lysosomes are indicated. Bars 200 nm. (B) LC3 staining in control and PD fibroblasts 
grown in complete medium (left panel) or starved in amino acid-free medium for 2 hours (right panel). Magnification 63×. Cells 
were fixed, permeabilized and immunostained with a polyclonal antibody to endogenous LC3 and visualized by fluorescence 
microscopy. LC3 staining shows multiple vesicles in intermediate and severe PD patients consistent with autophagosomes. 
Insets show high magnification views of autophagosomes. (C) Western blot analysis of LC3 in control and PD fibroblasts. Lanes 
1 to 4: cells grown in complete medium; lanes 5 to 8: cells starved in amino acid-free medium for 2 hours. Quantitative analysis 
by Image J of LC3-II peptides, normalized as ratio of LC3-II/β-actin (top) and LC3-II/LC3-I (bottom), showed that intermediate 
and severe PD fibroblasts have increased amounts of LC3-II as compared with control and juvenile PD fibroblasts.
Table 2: LC3 positive spots in PD fibroblast cell lines
Samples Percentage of cells with 1 to 10 of 
LC3 spots
Percentage of cells with 11 to 40 of 
LC3 spots
Percentage of cells with 41 to 200 of 
LC3 spots
Control 75% 20% 5%
Severe 10% 10% 80%PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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Pompe disease fibroblasts show expanded Golgi apparatus Figure 2
Pompe disease fibroblasts show expanded Golgi apparatus. Electron micrographs of severe Pompe disease fibroblasts 
(b) show longer Golgi cisternae. The cis-side (dotted red line) and trans-side (trans-Golgi network) of the Golgi apparatus are 
shown.PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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In control fibroblasts the CI-MPR signal was detectable in
early endosomal structures during the 18°C block, and
reached the juxtanuclear localization typical of the steady-
state within 15 minutes after the temperature shift. In PD
cells the CI-MPR signal intensity was reduced at 18°C and
the CI-MPR was never observed to reach the perinuclear
area after the temperature shift (Figure 5a).
The intensity of fluorescence was quantified, as described
in Methods, up to 60 minutes after the temperature shift
(Figure 5b). In control fibroblasts the intensity progres-
sively decreased over time. This reduction was probably
due to loss of fluorescent antibodies after several rounds
of CI-MPR recycling and/or delivery of the anti-CI-MPR
antibody to the late endosomes/lysosomes. In PD fibrob-
lasts the initial amount of fluorescence measured at 18°C
was reduced but the internalized fluorescence remained
fairly constant, leading to an inversion of the rate between
control and PD cells 15 to 30 minutes after the tempera-
ture shift (Figure 5b). This indicates that the antibody-CI-
MPR complexes are sequestered in PD cells and do not
efficiently recycle to the plasma membrane and/or deliver
the antibody to the late endosomes/lysosomes.
To assess whether the recycling defect of CI-MPR observed
in PD fibroblasts was accompanied by a general defect in
clathrin-mediated endocytosis we analyzed the uptake of
transferrin (Tf). The internalization of fluorescent Tf in the
early endocytic compartment was studied, keeping the
cells at 18°C for 60 minutes. The distribution of Tf and
transferrin receptor (TR) in control and mutant cells was
not substantially different (Figure 5c), suggesting that PD
Pompe disease fibroblasts show abnormal distribution of Golgi and trans-Golgi network markers Figure 3
Pompe disease fibroblasts show abnormal distribution of Golgi and trans-Golgi network markers. Immunofluo-
rescence analysis of markers of the Golgi apparatus. The cells were visualized by confocal fluorescence microscopy. Insets 
show high magnification views. The merged image of double staining is shown. The cells were fixed, permeabilized and stained 
with anti-Mannosidase II (green), anti-GM130 (red) (A), and with anti-Golgin 97 (green) (B). All markers showed abnormal dis-
tribution and expansion of the Golgi apparatus in intermediate and severe Pompe disease fibroblasts.PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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cells do not have a general defect in clathrin-mediated
endocytosis but a selective impairment of CI-MPR traffick-
ing and recycling along the endocytic pathway.
In order to understand where the cycling of CI-MPR is
arrested we investigated the nature of the peripheral struc-
tures positive for CI-MPR observed at the steady state in
PD fibroblasts. We found that a significant fraction of
them were positive for the autophagosome marker LC3 in
intermediate and severe PD fibroblasts (Figure 6a). To
gain insight into which fraction of CI-MPR came in con-
tact with autophagosomes, whether the one moving from
the TGN to the early and late endosomes, or the one recy-
cling back from the plasma membrane, we followed this
Pompe disease fibroblasts show abnormal intracellular localization of CI-MPR and reduced availability at the plasma membrane Figure 4
Pompe disease fibroblasts show abnormal intracellular localization of CI-MPR and reduced availability at the 
plasma membrane. (A) Immunofluorescence analysis of CI-MPR steady-state distribution in control and Pompe disease (PD) 
fibroblasts. The cells were grown on coverslips, fixed, permealized and stained with a mouse monoclonal antibody to CI-MPR. 
In intermediate and severe PD fibroblasts 55% and 75% of cells respectively showed reduced or mislocalized signal (right 
panel). Quantitative analysis was performed on 40 cells. (B) Co-staining of CI-MPR and TGN46. Cells were treated as above, 
stained with Alexa 594-conjugated donkey anti-mouse IgG (red channel) and Alexa 488-conjugated donkey anti-rabbit IgG 
(green channel) and visualized by confocal fluorescence microscopy. The right columns show the merged images of double 
staining of CI-MPR and TGN46. Intermediate and severe PD fibroblasts show abnormal distribution of both markers. (C) FACS 
analysis of CI-MPR expression at the plasma membrane of control and PD fibroblasts. Cells were incubated in ice with an anti-
CI-MPR and a secondary antibody labelled with phycoerythrin (PE). The rate of cells expressing CI-MPR at the plasma mem-
brane in PD fibroblasts is reduced in PD fibroblasts compared with controls and correlates with disease severity. The percent-
age is calculated by assuming that in control fibroblasts the rate is 100%. The data are representative of two independent 
experiments.PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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latter fraction through the internalized CI-MPR antibody.
The coefficient of co-localization was analyzed in cell
populations identified by the number of LC3-positive
spots. In PD fibroblasts we found that over time an
increasing amount of the CI-MPR antibody co-localized
with LC3, particularly in the fraction of cells showing the
highest accumulation of LC3-positive spots (Figure 6b).
Altogether these results suggest that CI-MPR in PD fibrob-
lasts is, at least in part, diverted towards the expanded
autophagosomal or autophagolysosomal compartments.
Endocytic recycling of CI-MPR is impaired in Pompe disease fibroblasts Figure 5
Endocytic recycling of CI-MPR is impaired in Pompe disease fibroblasts. To study the trafficking of CI-MPR through 
the endocytic pathway normal and severe fibroblasts grown on coverslip were incubated at 18° C for 1h with 15 ng/ml Alexa-
488-anti-CI-MPR antibody. The cells were washed and fixed (T0) or warmed to 37°C for 5, 15, 30, 60 min (T5, T15, T30, T60) 
before being fixed, permeabilized and stained with Alexa 488-conjugated donkey anti-mouse IgG to amplify the signal.   (A) In 
control fibroblasts the CI-MPR signal reaches its steady-state within 15 minutes. In severe fibroblasts signal intensity is reduced 
and the correct localization is not reached. (B) Average fluorescence intensity of internalized anti-CI-MPR antibody was quanti-
fied within the area concerning each single cell, using LSM 3.2 software (Zeiss). The analysis was performed on 40 cells. The 
quantitative analysis of fluorescence intensity (time 0-60 min) shows progressive decrease of signal intensity in control fibrob-
lasts. In severe Pompe disease (PD) fibroblasts the amount of fluorescence remains fairly constant, leading to an inversion of 
the rate between control and PD cells after 15 to 30 minutes. The error bars indicate the standard error. *=p≤0.05, 
**=p≤0.001. (C) The distribution of transferrin (Tf) and of trasferrin receptor (TR) is normal in PD fibroblasts. The cells were 
incubated with 50 mg/ml Alexa-488 transferrin at 18° C for 60 min, washed, fixed, permeabilized and stained with a trasferrin 
receptor antibody and Alexa-fluor 594 anti-rabbit IgG  antibody. Stained cells were visualized by confocal fluorescence micros-
copy. (D) Average fluorescence intensity of A488-Tf was quantified within the area concerning each single cell, using LSM 3.2 
software (Zeiss). The analysis was performed on 40 cells. Quantitative analysis of fluorescence intensity of the Tf signal shows 
comparable results in control and severe PD fibroblasts (p≤0.026). The error bars indicate the standard error.  PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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Figure 6 (see legend on next page)PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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The uptake of rhGAA is less efficient in fibroblasts from 
severe and intermediate PD patients
As a result of a deranged CI-MPR trafficking and of a
reduced availability of the receptor at the plasma mem-
brane it could be anticipated that the uptake and targeting
to lysosomes of lysosomal enzymes is impaired in PD
fibroblasts. We therefore investigated the uptake of rhGAA
in PD cells. Fibroblasts were cultured in the presence of
variable concentrations of rhGAA for 24 hours (to obtain
substantial and easily measurable enzyme activity within
cells and to allow processing of the precursor into the
mature active 76 kDa GAA molecular forms). Different
enzyme concentrations (0.5, 5, 50 μg/ml) of rhGAA in the
medium were used to study the uptake in a range of con-
centrations in which CI-MPR is not saturated. The correc-
tion of enzyme activity with the lowest concentration (0.5
μg/ml)  was negligible, whereas GAA activity was measur-
able after incubation with the highest rhGAA concentra-
tions. Correction of GAA deficiency was less efficient in
fibroblasts from patients with severe phenotypes, as com-
pared with the activity attained in cells from juvenile
patients (Figure 7a). Cells from intermediate patients
showed intermediate GAA levels after incubation with
rhGAA. All cell lines showed similar growth rates, suggest-
ing that the differences in GAA uptake were not correlated
to cellular growth. Uptake of rhGAA was completely abol-
ished by the addition to the culture medium of 5 mM
mannose-6-phosphate, thus confirming that enzyme
uptake was CI-MPR-dependent (data not shown).
The fate of internalized GAA in different cells was also
investigated by analyzing the uptake of Alexa Fluor 546-
labelled rhGAA. Fibroblasts were incubated with fluores-
cent rhGAA for variable times (2, 4 and 8 hours), fixed
and examined by fluorescence microscopy. Figure 7b
shows the results obtained after 2 hours of incubation in
a severe PD cell line, compared with control fibroblasts.
rhGAA is taken up efficiently by control fibroblasts, where
rhGAA signal appears clustered in granular structures,
which probably indicates correct delivery to the lysosomal
compartment. In contrast, in severe PD fibroblasts the
Alexa Fluor 546 signal is dispersed and less intense. Simi-
lar results were observed in cells incubated with fluores-
cent rhGAA for longer periods (4 and 8 hours) (data not
shown).
Evidence of an impaired targeting of rhGAA to lysosomes
was also obtained by western blot analysis of rhGAA mat-
uration in PD cells. All cells were incubated with 50 μg/ml
rhGAA, harvested and cell lysates subjected to western
blot analysis. The amount of the single GAA molecular
forms was quantitated by ImageJ analysis. In control
fibroblasts the endogenous GAA was subtracted from the
total amount detected after incubation with rhGAA. In
severe and intermediate PD fibroblasts the amount of the
enzyme internalized was reduced, confirming that GAA
uptake is less efficient as compared with control fibrob-
lasts (Figure 7c And 7d). In addition, the processing of the
enzyme was impaired in PD cells. Since the conversion of
the 100 kDa to 95 kDa precursor GAA molecular forms
into the mature 76 kDa enzyme takes place in the lyso-
somal compartment, these results indicate that the traf-
ficking of rhGAA to lysosomes is abnormal in PD
fibroblasts.
The studies on rhGAA uptake indicate that single rhGAA
administrations are not equally efficient in correcting
GAA deficiency in different PD fibroblasts, due to a
derangement of the CI-MPR distribution, and contribute
to the understanding of the variable response to ERT in
different patients. However, it may be speculated that
repeated administrations of rhGAA are more effective in
correcting GAA activity and, possibly, the cellular pheno-
type in PD cells. We therefore studied the effects of a con-
tinuous supply of GAA in PD fibroblasts, extending the
incubation time of PD fibroblasts with rhGAA for several
days. To this purpose fibroblasts were incubated for 0 to 6
days and the medium containing 50 μg/ml rhGAA was
refreshed every other day. Under these conditions GAA
activity increased steadily and within 2 to 4 days
CI-MPR co-localizes partially in LC3 positive vesicle in Pompe disease fibroblasts Figure 6 (see previous page)
CI-MPR co-localizes partially in LC3 positive vesicle in Pompe disease fibroblasts. (A) Steady-state analysis of CI-
MPR and LC3 positive vesicles shows co-localization in severe and intermediate Pompe disease (PD) fibroblasts. The cells were 
fixed, permeabilized and stained with a mouse monoclonal antibody to CI-MPR and a rabbit polyclonal antibody to LC3 and 
Alexa 594-conjugated donkey anti-mouse IgG (red channel) and Alexa 488-conjugated donkey anti-rabbit IgG (green channel) 
antibodies. Stained cells were visualized by confocal fluorescence microscopy. The right columns show the merged images of 
double staining of CI-MPR and LC3. Magnification 63×. Insets show high magnification views. (B) Quantitative analysis of CI-
MPR and LC3 co-localization after internalization of CI-MPR. The cells grown on coverslips were incubated at 18°C for 1 hour 
with 15 ng/ml Alexa 488-anti-CI-MPR monoclonal antibody. The cells were washed and fixed (0 min) or warmed to 37°C for 5, 
15, 30 minutes (as indicated) before being fixed, permeabilized and stained with anti-LC3. The rate of CI-MPR/LC3 co-localiza-
tion was determined using performed by LSM 3.2 software (Zeiss). The analysis was performed on at least 20 cells per sample. 
In severe PD fibroblasts, co-localization is higher as compared with control and CI-MPR, indicating sequestration of CI-MPR in 
autophagosomes.PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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approached normal or near-normal values in intermedi-
ate and juvenile PD cell lines. In cells from a patient with
severe PD a complete correction of GAA activity required
a longer incubation with rhGAA, and GAA activity showed
a 'catch-up' increase between days 4 and 6, eventually
reaching normal values (Figure 8a). This suggests severely
affected PD cells may be more difficult to treat and may
require additional duration of therapy.
In the severe PD cell line we also studied whether pro-
longed incubation with rhGAA is effective in rescuing the
abnormal CI-MPR distribution. To this purpose we per-
formed an immunofluorescence analysis of CI-MPR in
these cells after 6 days of rhGAA treatment (see above).
Scoring of CI-MPR distribution showed that the number
of cells showing a reduced and/or mislocalized signal had
decreased after treatment to approximately 44%, while in
The uptake of rhGAA is defective in fibroblasts from severe and intermediate Pompe disease patients Figure 7
The uptake of rhGAA is defective in fibroblasts from severe and intermediate Pompe disease patients. (A) 
Pompe disease (PD) fibroblasts were incubated for 24 hours with different concentrations of rhGAA (0.5, 5, 50 μg/ml) in the 
medium and GAA activity was assayed. Correction of GAA activity in severe and intermediate fibroblasts from patients 1 to 3 
is less efficient as compared with juvenile fibroblasts from patients 4 and 5. (B) Uptake of Alexa Fluor 546-labeled rhGAA in 
control and PD fibroblasts. The cells were grown on coverslips and were incubated with fluorescent rhGAA for different times 
(2, 4 and 8 hours), washed, fixed and visualized by fluorescence microscopy. The images show the results obtained after 2 
hours of incubation. In severe PD fibroblasts a diffuse staining of labelled rhGAA is observed, in contrast with the granular pat-
tern typical of lysosomal staining in control fibroblasts. Magnification 63×. (C) Western-blot analysis of GAA polypeptides 
shows reduced processing of rhGAA precursor into the 76 kDa mature enzyme, confirming impaired transport of rhGAA to 
the lysosomal compartment. Lysates from untreated control fibroblasts and control and PD fibroblasts treated with rhGAA for 
4 hours were analyzed. (D) ImageJ quantitative analysis of the rhGAA molecular forms. The intensity of bands is normalized as 
ratio of rhGAA/β-actin.PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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Figure 8 (see legend on next page)PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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untreated cells cultured in parallel the rate of cells show-
ing abnormal CI-MPR localization had remained
unchanged (approximately 73%) (Figure 8b). This indi-
cates that ERT is effective in rescuing the cellular pheno-
type and that a normalization of the CI-MPR distribution
is essential for correction of GAA activity. The rapid 'catch-
up' increase of GAA activity observed in the severe cell line
between 4 and 6 days is probably the consequence of a
restored CI-MPR distribution and function.
The uptake of rhGAA is less efficient in fibroblasts from 
other LSDs
It is possible to speculate that a derangement of cellular
functions and morphology, triggered by intralysosomal
substrate storage, is a generalized phenomenon in LSDs.
This issue is important for possible implications in the
diseases for which ERT is available. Although our work
was focused on a single model of LSD, PD, we also studied
the uptake of rhGAA in cells from other LSDs.
We studied rhGAA uptake in fibroblasts from two muco-
polysaccharidoses (MPS), Hunter disease (MPS II) and
Maroteaux-Lamy disease (MPS VI), both characterized by
generalized accumulation of glycosaminoglycans, and in
mouse embryonic fibroblasts (MEFs) from a mouse
model of multiple sulphatase deficiency (MSD), obtained
by disruption of Sumf1  [25]. In all of these cell lines
rhGAA, expressed as the difference between baseline activ-
ity and the activity after incubation with the recombinant
enzyme for 24 hours, appeared reduced as compared with
that observed in control fibroblasts (Figure 9a) and in
control MEFs (Figure 9b).
Discussion
We have demonstrated that fibroblasts from patients with
PD show abnormalities of cellular morphology, including
intracellular storage of glycogen, expansion of the
autophagic compartment, disorganization of the Golgi
apparatus and of the TGN, and disruption of intracellular
CI-MPR localization. The derangement of CI-MPR distri-
bution apparently correlates with disease severity and has
functional consequences, resulting in an impaired uptake
of exogenous rhGAA in cells from early-onset PD patients.
The demonstration in vitro of a variable efficacy of rhGAA
in correcting GAA activity in different cell lines has impli-
cations for the efficacy of ERT in vivo.
Although cellular pathology in PD has been mostly inves-
tigated in muscle cells, the observation of intracellular
storage in cultured PD fibroblasts is not unexpected. It has
been shown that fibroblasts, an in vitro system that can be
obtained by procedures that cause only mild discomfort
to patients, do accumulate glycogen and that GAA defi-
ciency and glycogen storage correlates with age at onset
and clinical course of the disease [26]. In PD fibroblasts
we observed glycogen storage not only in lysosomes and
in MVBs, but also in the cytoplasm. This may be a conse-
quence of a reduced clearance of cytoplasmic glycogen by
a less efficient autophagic machinery.
The autophagic compartment was in fact abnormal in PD
fibroblasts, particularly in cells from severe and interme-
diate patients. Autophagy is a physiological catabolic
pathway through which cytosolic proteins and organelles,
such as mitochondria, are sequestered by double-mem-
brane vesicles (autophagosomes or autophagic vesicles)
and degraded in the lysosomal compartment after
autophagosome-lysosome fusion [27]. An impairment of
autophagy has recently been implicated in the pathophys-
iology of LSDs, with mechanisms that remain still par-
tially understood [28-30].
In PD, an age-dependent expansion of the autophago-
somal compartment was observed in a PD knock-out
mouse model obtained by disruption of the murine Gaa
gene and in muscle biopsies from PD patients [31-34].
These studies showed for the first time the presence of
abnormal autophagy in PD tissues and correlated the
presence of such abnormalities with a poor response to
ERT, although the abnormalities of the autophagosomal
compartment appeared to be confined to type II muscle
cells. Our results add further information on the derange-
Correction of GAA activity in Pompe disease fibroblasts Figure 8 (see previous page)
Correction of GAA activity in Pompe disease fibroblasts. (A) To study the time course of GAA correction, fibroblasts 
from Pompe disease (PD) patients were incubated in the presence of 50 μg/ml rhGAA for 2, 4 and 6 days. The medium and the 
enzyme were refreshed every other day. After the times indicated the cells were harvested and GAA activity measured. 
Untreated fibroblasts were cultured and harvested in parallel. Complete correction of GAA activity in severe PD fibroblasts 
requires 6 days and is slower than in the other cell lines. (B) CI-MPR intracellular distribution in untreated severe fibroblasts 
and severe fibroblasts treated for 6 days with rhGAA. The cells were fixed, permealized and stained with mouse monoclonal 
antibody to CI-MPR and Alexa 488-conjugated donkey anti-mouse IgG secondary antibody. Stained cells were visualized by flu-
orescence microscopy. * = p ≤ 0.000003, chi-square test. The data were analyzed using EpiInfo (version 3.3, 2004). (C) CI-MPR 
distribution was scored by two independent researchers. The analysis was performed on 10 images, each containing 40 cells. 
After rhGAA treatment for 6 days the rate of PD cells showing a reduced and/or mislocalized signal is decreased to 40%, as 
compared with untreated cell (90%). p ≤ 0.026PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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The uptake of rhGAA is defective in fibroblasts from other lysosomal storage disorders Figure 9
The uptake of rhGAA is defective in fibroblasts from other lysosomal storage disorders. (A) Human control 
fibroblasts and fibroblasts from MPSII and MPSVI patients and (B) mouse embryonic fibroblasts (MEF) from control mice and 
Sumf1-/- mice were incubated with rhGAA (50 μg/ml) for 24 hours. GAA activity is expressed as nmol 4-methylumbelliferone 
liberated/mg protein/h. Activities are expressed as the difference between the activity after 24 hours of incubation and baseline 
activity. All mutant cell lines analyzed show reduced GAA activity as compared with control cells.PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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ment of the autophagic pathway in PD as they indicate
that abnormalities of autophagy are a generalized phe-
nomenon in PD, detectable in cells other than specific
muscle cells and that fibroblasts may represent a useful
tool for in vitro studies aimed at investigating the mecha-
nisms underlying these abnormalities.
We found abnormalities of Golgi and TGN morphology
both by EM analysis and by immunofluorescence studies
using known markers of these organelles. A large number
of genes are involved in the correct organization of the
Golgi apparatus [35,36] and it might be an intriguing and
challenging task to identify putative targets of glycogen
storage among these genes and thus clarify the mecha-
nisms leading to Golgi abnormalities in PD. In principle,
an abnormal retrograde trafficking of membranes may
play a role in disrupting the normal organization of the
Golgi apparatus, as it has been shown that this mecha-
nism is important in allowing the turnover of membranes
and membrane-bound proteins and in maintaining the
integrity of cellular organelles [37].
The abnormalities of Golgi apparatus and the TGN may
explain, at least in part, the changes in the distribution of
CI-MPR, a membrane-bound protein mostly localized in
Golgi and the TGN. CI-MPR traffics within cells following
different itineraries in which transit to the TGN is an
important stage, such as the lysosomal enzyme biosyn-
thetic pathway, from the TGN to the late endosomes and
back to the TGN; the endosomal pathway from the
plasma membrane to the ERC, where most of it (84%,
[38]) recycles back to the plasma membrane; and an addi-
tional route that diverges from the endocytic pathway and
reaches late endosomes and from these organelles carries
CI-MPR again to the TGN [39].
The abnormal CI-MPR distribution observed in PD
fibroblasts may be the result of a derangement in one or
more of these pathways. We focused on the endocytic
pathway, as this route is important for ERT. The rationale
of ERT relies upon the demonstration that exogenous lys-
osomal enzymes are internalized through the interaction
of mannose or mannose-6-phosphate ligands, present on
the carbohydrate chains of the enzymes, with their spe-
cific receptors. An intact and efficient mannose-6-phos-
phate pathway is therefore essential for the efficacy of
such therapeutic approach and it could reasonably be
anticipated that an impaired trafficking of CI-MPR
through the endocytic pathway may impact the efficiency
of lysosomal enzyme uptake and thus the efficacy of ERT
in vivo.
Time-lapse experiments using a severe PD cell line, show-
ing the most striking abnormalities of cellular phenotype
and of CI-MPR intracellular distribution, indicated that
the route from the plasma membrane to the TGN is
impaired. This may be the consequence of an abnormal
retrograde trafficking of the CI-MPR from the late endo-
somes to the TGN. CI-MPR traffics together with Tf and
TR, in the early endosomal compartment and in the ERC,
where they recycle back to the plasma membrane. Since
we did not find abnormalities of Tf and TR distribution in
the PD cells examined, it is likely that the disruption of CI-
MPR trafficking occurs at the late endosomal compart-
ment and in the retrograde route to the TGN. In this
respect it is worth mentioning that abnormal retrograde
CI-MPR transport (such as due to inhibition of PACS1
and AP1), resulted in disruption of its normal localization
[40-42].
The finding of increased co-localization of CI-MPR with
LC3, a marker of the autophagosomes and autophagolys-
osomes, supports the hypothesis of an impaired retro-
grade trafficking of CI-MPR from late endosomes to the
TGN, and indicates that, at least in part, CI-MPR is seques-
tered in relatively inert vesicles deriving from the fusion of
autophagosomes with substrate-engulfed lysosomes.
Sequestration of CI-MPR in these organelles leads to a
depletion of functionally available CI-MPR at the plasma
membrane (Figure 10).
A consequence of the reduced availability of CI-MPR at
the plasma membrane is that the uptake of exogenous
enzymes is less efficient. Defective uptake of another lyso-
somal hydrolase, acid sphingomyelinase, was demon-
strated by Dhami and Schuchman in macrophages from a
Niemann-Pick A mouse model [43]. The authors hypoth-
esized that lipid accumulation in macrophages leads to
abnormalities in CI-MPR trafficking and/or degradation,
although they did not provide a morphological analysis of
CI-MPR distribution and trafficking in their cell system
supporting this hypothesis.
We showed that correction of GAA activity by rhGAA was
impaired in individual PD cell lines. In principle, poor
correction of GAA activity may result from impaired
uptake or from reduced enzyme maturation and stability.
The combination of the results of uptake studies of fluo-
rescent-labelled enzyme and the results of western blot
analysis of rhGAA processing indicates that both mecha-
nisms contribute to a reduced efficacy of ERT in PD.
In our studies the rate of rhGAA uptake by PD fibroblasts
varied among different cell lines and correlated with the
degree of abnormality of CI-MPR distribution. We sug-
gested that the abnormalities of CI-MPR distribution and
GAA uptake correlate with disease severity, although other
factors may also be implicated. The observation that cells
from PD patients with the severe phenotypes are less effi-
cient in internalizing rhGAA is apparently in contrast withPathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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Schematic representation of CI-MPR trafficking in the cells Figure 10
Schematic representation of CI-MPR trafficking in the cells. CI-MPR follows different routes, including the biosyn-
thetic pathway from the trans-Golgi network (TGN), where it binds and delivers newly synthesized lysosomal hydrolases to 
the late endosomal compartment. A fraction (approximately 10%) of CI-MPR is located on the cell surface, where it mediates 
the uptake of lysosomal enzymes, is internalized in the endocytic pathway and recycles through the endocytic recycling com-
partment (ERC), again to the plasma membrane. The finding of increased co-localization of CI-MPR with LC3 in Pompe disease 
(PD) fibroblasts indicates that in these cells part of the CI-MPR is diverted from its normal routes and is sequestered in 
autophagosomes and autophagolysosomes. Since transferrin and transferring receptor trafficking is not affected in PD fibrob-
lasts, it is likely that the disruption of CI-MPR trafficking occurs at the late endosomal compartment and in the retrograde 
route to the TGN.PathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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the observation that the best results with ERT are obtained
in patients with the infantile classic PD. In fact, in these
patients treatment is started at an earlier age as compared
with late-onset patients, and it is reasonable to think that
if the abnormalities of cell functions are triggered by sub-
strate storage, then the start of treatment before extensive
storage occurs, particularly in the tissues which are the
main targets of disease (cardiac and skeletal muscle), may
prevent the development of these abnormalities.
The implications of our results for treatment with ERT in
PD are evident. ERT has proved to be particularly chal-
lenging in a subset of PD patients, whereas in other
patients the efficacy of ERT was excellent. The reasons for
such a variable response to ERT are still controversial. Age
at start of treatment is surely one of the most important
factors for the outcome of ERT. In addition, other factors
have been proposed. An effect due to the poor response of
type II muscle fibres, initially suggested by Fukuda et al
[31] was not confirmed by a subsequent study [44]. The
role of other factors such as different genetic backgrounds
and the different impacts of GAA gene mutations has not
been fully investigated.
Our results identify the role of additional factors, such as
the derangement of cellular functions and disruption of
CI-MPR localization, implicated in the variable response
to ERT.
ERT is based on weekly or biweekly infusions, depending
on treatment protocols specific for each LSD. In PD, clin-
ically detectable results are expected to be evident only
after long-term treatments. An important question is
whether correction of GAA deficiency by ERT may start a
virtuous mechanism by correcting cellular abnormalities,
restoring normal function of the CI-MPR pathway and, in
turn, further improving the efficacy of rhGAA uptake. To
address this question we incubated PD fibroblasts with
rhGAA for long periods, up to 6 days. This resulted in
increased GAA activity in all cell lines. However, correc-
tion was hampered in the cells with prominent abnormal-
ities of CI-MPR distribution. In these cells a 'catch-up'
increase, eventually leading to normal intracellular GAA
activity, was observed in association with an improved CI-
MPR cellular distribution.
This experiment provides useful information about ERT.
First, it further supports the correlations between CI-MPR
distribution and efficacy of ERT. In addition, our results
support the idea that ERT may correct the abnormalities of
cellular morphology and function. On the other hand, it
should be mentioned that the experimental conditions we
used, with relatively high rhGAA concentrations in the
culture medium and continuous supply of new enzyme,
differ from those used in human therapy. PD patients (as
well as patients with other LSDs treatable with ERT) are
treated with single rhGAA infusions every week or every
other week and the concentrations attained in plasma
return to baseline levels a few days after the infusion. Our
results may therefore suggest that ERT treatment protocols
should be reconsidered and that other approaches, such
as gene therapy (providing a continuous supply of
enzyme either locally or from 'factory' organs) may result
in more effective rescuing of cell and tissue damage.
An intriguing question is whether the results obtained in
PD fibroblasts indicate a mechanism shared by other
LSDs, or are the result of the storage of a specific substrate.
Although it was not in the scope of this study to provide a
general model for all LSDs, we investigated whether
rhGAA uptake is also affected in fibroblasts from patients
with other LSDs. To this purpose we studied the uptake of
rhGAA by MEFs from an animal model of MSD, generated
by the disruption of the Sumf1  gene [25]. This model
seems particularly suitable to address this point as in MSD
the simultaneous deficiency of an entire family of lyso-
somal hydrolases causes substantial storage of a range of
sulphated substrates. Also in these cells, and in fibroblasts
from MPS II and VI, the uptake of rhGAA was less efficient
as compared with controls. These observations are in
favour of the hypothesis of a common abnormality in
LSDs and indicate the need for similar studies, with the
specific recombinant enzymes, in cell lines and animal
models of other LSDs.
Conclusion
Recent studies have shown that in LSDs substrate storage
triggers secondary events leading to abnormalities of cell
morphology and function. In fibroblasts from PD we
demonstrated that a consequence of these abnormalities
is a deranged distribution and function of the CI-MPR.
These in vitro data may have implications for the response
to ERT in individual patients and should be investigated
in vivo in PD patients and in other LSDs. Our studies may
also indicate the need for therapies targeted to these cellu-
lar abnormalities. If a strategy to improve cellular func-
tions is found, this may have a significant impact on the
efficacy of ERT and may suggest a multi-drug therapeutic
approach tailored to individual patients.
Methods
Cell lines
Cells from a classic infantile (patient 1; [45]), two inter-
mediate (patients 2 and 3; 1 and 2 in [46], respectively)
and two juvenile (patients 4 and 5; cases 3 and 5 in [45],
respectively) PD patients were available in the laboratory
of the Department of Paediatrics, University of Naples,
Italy. Each experiment was performed in all cell lines,
although for some of the experiments data from single
patients of each phenotype are shown. The experimentsPathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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on CI-MPR, Tf and TR trafficking and on CI-MPR immu-
nolocalization after long-term rhGAA correction were
only done in the cell line from patient 1, which showed
the most striking abnormalities of cell morphology.
Fibroblasts from patients with MPS II and MPS VI were
provided by M Filocamo, G Gaslini Institute and Telethon
Genetic Biobank Network, Genoa, Italy (Telethon grant
GTB07001A). Sumf1-/- MEFs, and control MEFs were avail-
able at the Telethon Institute of Genetics and Medicine,
Naples, Italy. Normal age-matched control fibroblasts,
available in the laboratory of the Department of Paediat-
rics, University of Naples, Italy, were studied for compari-
son.
All cell lines were grown at 37°C with 5% CO2, in Dul-
becco's modified Eagle's medium (DMEM, from Invitro-
gen, NY, USA) and 10% foetal bovine serum (FBS)
(Sigma-Aldrich, St Louis, MO, USA), supplemented with
100 U/ml penicillin and 100 μg/ml streptomycin. To
induce starvation and stimulate autophagy, fibroblasts
were cultured under amino acid deprivation in Earle' Bal-
anced Salt Solution (from Invitrogen, NY, USA) for 2
hours, before being analyzed.
Reagents
The primary antibodies used for immunofluorescence
and western blot analysis were: anti-LC3 rabbit polyclonal
antiserum (Novus Biologicals, Littleton, CO, USA); anti-
β-actin mouse monoclonal antibody (Sigma-Aldrich);
anti-human LAMP2 mouse monoclonal antibody (Santa
Cruz Biotechnology, CA, USA); anti-human CI-MPR
mouse monoclonal antibody, anti-human TGN38 goat
polyclonal antiserum and anti-human mannosidase II
rabbit polyclonal antiserum (Novus Biologicals); anti-
GM130 mouse monoclonal antibody (BD Transduction
Laboratories); anti-golgin-97 rabbit polyclonal antiserum
(provided by Edward KL Chan); anti-TGN46 sheep poly-
clonal antiserum (Serotec); anti-γ-adaptin mouse mono-
clonal antibody (BD Transduction Laboratories); anti-
transferrin receptor mouse monoclonal antiserum
(Zymed Laboratories). Secondary antibodies were: anti-
rabbit, anti-mouse and anti-goat conjugated to Alexa
Fluor 488 or 596 (Molecular Probes, Eugene, OR, USA);
HRP-conjugated anti-rabbit or anti-mouse IgG (Amer-
sham, Freiburg, Germany).
Labelling of rhGAA and anti-CI-MPR antibody was per-
formed by using a Protein Labelling Kit and Alexa Fluor
488 Monoclonal Antibody labelling kit (Molecular
Probes, Eugene, OR, USA), respectively. rhGAA
(Myozyme) was purchased from Genzyme Co (Naarden,
the Netherlands).
Immunofluorescence studies
To study the distribution of LC3, CI-MPR, cis-Golgi and
TGN markers, Tf and TR, human fibroblasts grown on
coverslips were fixed using methanol, permeabilized
using 0.1% saponin and blocked with 0.01% saponin, 1%
FBS diluted in PBS for 1 hour. The cells were incubated
with the primary antibodies, with secondary antibodies in
blocking solution and then mounted with vectashield
mounting medium with DAPI (Vector Laboratories, Burl-
ingame, CA).
For experiments shown in Figures 4 and 6 photographs
were taken by using a Zeiss Axioplan 2 fluorescence
microscope (Carl Zeiss, Jena, Germany) integrated with
the AxioCam MR camera and 63× oil objective with a 1.25
numerical aperture lens. Digital images were captured by
using a digital colour Zeiss Axiocam 1300×1030 pixel and
Zeiss AxioVision software. For experiments shown in Fig-
ures 3 and 5 confocal microscopy analysis was performed
using a Leica laser-scanning confocal image system TCS
SP2 AOBS (Leica Microsystems, Heidelberg, Germany).
Samples were excited with a 488 nm Ar laser and a 594
nm He-Ne laser. Samples were vertically scanned from the
bottom coverslip with a total depth of 50 μm and a 63×
(1.32 NA) HP PLAPO oil-immersion objective. A total of
10 z-line scans with a step distance of 0.2 mm was col-
lected and maximum intensity projections were generated
with Leica Confocal Software (Leica Microsystems, Hei-
delberg, Germany).
In experiments shown in Figures 4 and 8 CI-MPR distribu-
tion was scored by two independent researchers. Results
of these analyses were obtained on a total of 40 cells for
each cell line.
Electron microscopy analysis
Cells were fixed for 30 minutes (room temperature) with
1% glutaraldehyde prepared in Hepes 0.2 M and proc-
essed for EM as described previously [47]. The percentage
of endolysosome volume occupied by glycogen was meas-
ured using AnalySIS software (Soft Imaging Systems
GmbH, Munster, Germany).
Western blot analysis
To study GAA processing and LC3 maturation, fibroblast
extracts were subjected to western blot analysis. The cells
were harvested, washed in PBS and lysed in cold RIPA
buffer containing Complete Protease Inhibitor Cocktail
(Roche Diagnostics, Mannheim, Germany) for 30 min-
utes on ice. Lysates were precleared by centrifugation at
10,600 g for 10 minutes at 4°C. Equal amounts (20 μg
protein) of fibroblast extracts were subjected to SDS-
PAGE electrophoresis (7% or 10% acrylamide in different
experiments) and proteins were transferred to PVD mem-
brane (Millipore, Billerica, MA, USA). Anti-human GAAPathoGenetics 2008, 1:6 http://www.pathogeneticsjournal.com/content/1/1/6
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and anti-human LC3 rabbit polyclonal antisera were used
as primary antibodies to detect GAA polypeptides and
LC3-I and LC3-II (Novus Biological, Littleton, CO, USA),
respectively; to detect β-actin a monoclonal mouse anti-
body was used. Immunoreactive proteins were detected
by chemiluminescence (ECL, Amersham, Freiburg, Ger-
many). Western blots show representative results from
one of three experiments. Quantitative analysis of band
intensity was performed using ImageJ.
FACS analysis
To obtain a quantitative analysis of CI-MPR availability at
the plasma membrane, PD and control fibroblasts were
suspended in blocking buffer (1% FBS in PBS). After incu-
bating for 30 minutes on ice, the cells were washed and
suspended in blocking buffer containing titered excess of
CI-MPR monoclonal antibody for 30 minutes on ice.
Cells were then washed, re-suspended in blocking buffer
containing phycoerythrin-conjugated anti-mouse second-
ary antibody for 30 minutes on ice, filtered through 70
μm filcons (BD Biosciences Pharmingen, San Jose, CA,
USA) and analyzed using a BD Biosciences FACS Aria (BD
Biosciences Pharmingen, San Jose, CA, USA).
Uptake of rhGAA and correction of GAA activity
To study rhGAA uptake and correction of GAA activity PD,
MPS II and MPS VI fibroblasts were incubated with differ-
ent concentrations (0.5, 5, 50 μg/ml) of rhGAA for 24
hours. The cells were then harvested and cell pellets were
washed twice with PBS, resuspended in the water and dis-
rupted by five cycles of freeze-thawing. GAA activity was
assayed as already described [45]. Protein concentrations
were determined in total homogenates by the Bradford
assay (Bio-Rad, Hercules, CA).
To study the time course of GAA correction, fibroblasts
from a patient with severe PD were incubated in the pres-
ence of 50 μg/ml rhGAA for 2, 4 and 6 days. The medium
and the enzyme were refreshed every other day. After the
times indicated the cells were harvested and GAA activity
assayed as indicated above. Untreated cells were cultured
and analyzed in parallel. Part of the cells was analyzed for
CI-MPR localization as indicated above.
To study the uptake of fluorescent rhGAA, the enzyme was
labelled and purified using the Alexa Fluor 546 Protein
labelling kit (Molecular Probes), according to the manu-
facturer's instructions. Fibroblasts were incubated with
rhGAA (50 μg/ml) for different times 2, 4 and 8 hours.
The cells were fixed in methanol for 5 minutes and exam-
ined on a fluorescence microscope Axioplan 2 (Zeiss,
Thornwood, NY, USA) as described above.
Endocytic recycling of CI-MPR and transferrin uptake
To study trafficking through the endocytic pathway,
fibroblasts were incubated in DMEM 20 mM Hepes with-
out FCS with 15 ng/ml Alexa 488-anti-CI-MPR antibody
for 60 minutes at 18°C. The cells were washed in DMEM
20 mM Hepes with 10% FCS and fixed (0 min) or warmed
to 37°C for 5, 15, 30, 60 minutes before fixation. The cells
were permeabilized and stained with Alexa Fluor 488
anti-mouse IgG to amplify the signal or with anti-LC3 pri-
mary antibody and Alexa Fluor 594 anti-rabbit IgG.
Stained cells were visualized by confocal fluorescence
microscopy as indicated. Quantitative analysis of CI-MPR
fluorescence intensity of was performed by LSM 3.2 soft-
ware (Zeiss). The percentage of CI-MPR/LC3 co-localiza-
tion was determined using by LSM 3.2 software (Zeiss).
The analysis was performed on 40 cells.
To study the uptake of Tf, cells were incubated with 50 μg/
ml Alexa 488-transferrin for 60 minutes at 18°C, as indi-
cated, fixed and stained with TR antibody and Alexa Fluor
594 anti-rabbit IgG.
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